Merck Reports P-III (STELLAR) Trial Results of Sotatercept for the Treatment of Pulmonary Arterial Hypertension
Shots:
- The P-III (STELLAR) trial evaluates sotatercept (0.7mg/kg, SC, q3w) vs PBO as an add-on to background therapy in 324 adult patients with PAH
- The trial met its primary efficacy outcome measure which showed an improvement in 6MWD from baseline @24wk. & exercise capacity. The trial also met its secondary efficacy outcome measures incl. the proportion of patients who achieved improvement in 6MWD, NT-proBNP level & WHO FC, or maintenance of WHO FC II & TTCW. The safety profile was consistent with that observed in the P-II study
- Sotatercept is an activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein & has received BTD from the US FDA & Priority Medicines designation from the EMA for PAH
Ref: Merck | Image: Merck
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
